Recent research trends and updates on nonalcoholic fatty liver disease

키워드

참고문헌 (82)

1. 강윤구, "Estimated Prevalence of Adolescents with Nonalcoholic Fatty Liver Disease in Korea", Journal of Korean Medical Science, 33(14), pp.29~38 (2018), 대한의학회
2. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : Practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
3. Sanyal AJ, "Endpoints and clinical trial design for nonalcoholic steatohepatitis", Hepatology, 54, pp.344~353 (2011)
4. Konerman MA, "Pharmacotherapy for NASH : current and emerging", J Hepatol, 68, pp.362~375 (2018)
5. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
6. Brunt EM, "Nonalcoholic steatohepatitis : a proposal for grading and staging the histological lesions", Am J Gastroenterol, 94, pp.2467~2474 (1999)
7. Ludwig J, "Nonalcoholic steatohepatitis : Mayo Clinic experiences with a hitherto unnamed disease", Mayo Clin Proc, 55, pp.434~438 (1980)
8. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
9. Brunt EM, "Nonalcoholic fatty liver disease(NAFLD)activity score and the histopathologic diagnosis in NAFLD : distinct clinicopathologic meanings", Hepatology, 53, pp.810~820 (2011)
10. Sanyal AJ, "Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop", Hepatology, 61, pp.1392~1405 (2015)
11. Liou I, "Natural history of nonalcoholic steatohepatitis", J Clin Gastroenterol, 40(Suppl 1), pp.S11~S16 (2006)
12. Fassio E, "Natural history of nonalcoholic steatohepatitis : a longitudinal study of repeat liver biopsies", Hepatology, 40, pp.820~826 (2004)
13. Ong JP, "Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis", Gastroenterology, 123, pp.375~378 (2002)
14. Cotrim HP, "Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history?", Am J Gastroenterol, 95, pp.3018~3019 (2000)
15. Kaswala DH, "Fibrosis Assessment in Nonalcoholic Fatty Liver Disease(NAFLD)in 2016", Dig Dis Sci, 61, pp.1356~1364 (2016)
16. Tapper EB, "Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD", Nat Rev Gastroenterol Hepatol, 15, pp.274~282 (2018)
17. Younossi ZM, "Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis", Hepatology (2017)[DOI]
18. Loomba R, "Role of imaging-based biomarkers in NAFLD : recent advances in clinical application and future research directions", J Hepatol, 68, pp.296~304 (2018)
19. Rensen SS, "Activation of the complement system in human nonalcoholic fatty liver disease", Hepatology, 50, pp.1809~1817 (2009)
20. Friedrich-Rust M, "Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis", BMC Gastroenterol, 10, pp.103~ (2010)
21. Angulo P, "The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD", Hepatology, 45, pp.846~854 (2007)
22. Shah AG, "Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 7, pp.1104~1112 (2009)
23. Ratziu V, "A critical review of endpoints for non-cirrhotic NASH therapeutic trials", J Hepatol, 68, pp.353~361 (2018)
24. Kotronen A, "Liver fat in the metabolic syndrome", J Clin Endocrinol Metab, 92, pp.3490~3497 (2007)
25. Yokoo T, "Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T", Radiology, 251, pp.67~76 (2009)
26. Meisamy S, "Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat : blinded comparison with MR spectroscopy", Radiology, 258, pp.767~775 (2011)
27. Noureddin M, "Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials", Hepatology, 58, pp.1930~1940 (2013)
28. Castera L, "Noninvasive evaluation of NAFLD", Nat Rev Gastroenterol Hepatol, 10, pp.666~675 (2013)
29. Al-Dayyat HM, "Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors", Diabetes Metab Syndr (2018)[DOI]
30. Issa D, "Future therapy for non-alcoholic fatty liver disease", Liver Int, 38(Suppl 1), pp.56~63 (2018)
31. Mudaliar S, "Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease", Gastroenterology, 145, pp.574~582 (2013)
32. Cariou B, "Dual peroxisome proliferator-activated receptor α", δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects, 2013, pp.36, 2923~2930
33. Matthews DR, "Homeostasis model assessment : insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man", Diabetologia, 28, pp.412~419 (1985)
34. Bonora E, "Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity : studies in subjects with various degrees of glucose tolerance and insulin sensitivity", Diabetes Care, 23, pp.57~63 (2000)
35. Isokuortti E, "Use of HOMA-IR to diagnose non-alcoholic fatty liver disease : a population-based and inter-laboratory study", Diabetologia, 60, pp.1873~1882 (2017)
36. Pavlides M, "Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity", Liver Int, 37, pp.1065~1073 (2017)
37. Cusi K, "Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus : a randomized trial", Ann Intern Med, 165, pp.305~315 (2016)
38. Ratziu V, "Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening", Gastroenterology, 150, pp.1147~1159 (2016)
39. Belfort R, "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis", N Engl J Med, 355, pp.2297~2307 (2006)
40. Ratziu V, "Rosiglitazone for nonalcoholic steatohepatitis : one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy(FLIRT)Trial", Gastroenterology, 135, pp.100~110 (2008)
41. Ratziu V, "A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis", Hepatology, 55, pp.419~428 (2012)
42. Ratziu V, "A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis", J Hepatol, 54, pp.1011~1019 (2011)
43. Vilar-Gomez E, "Non-invasive assessment of non-alcoholic fatty liver disease : clinical prediction rules and blood-based biomarkers", J Hepatol, 68, pp.305~315 (2018)
44. Stasi C, "Non-invasive assessment of liver fibrosis : between prediction", prevention of outcomes and cost-effectiveness, 2016, pp.22, 1711~1720
45. Castera L, "Noninvasive evaluation of nonalcoholic fatty liver disease", Semin Liver Dis, 35, pp.291~303 (2015)
46. Wong VW, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease", Hepatology, 51, pp.454~462 (2010)
47. Castéra L, "Pitfalls of liver stiffness measurement : a 5-year prospective study of 13, 369 examinations", Hepatology, 51, pp.828~835 (2010)
48. Wong VW, "Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease", Am J Gastroenterol, 107, pp.1862~1871 (2012)
49. Harrison SA, "NGM282 for treatment of non-alcoholic steatohepatitis : a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial", Lancet, 391, pp.1174~1185 (2018)
50. Armstrong MJ, "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN) : a multicentre, double-blind, randomised, placebocontrolled phase 2 study", Lancet, 387, pp.679~690 (2016)
51. Safadi R, "The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 12, pp.2085~2091 (2014)
52. Neuschwander-Tetri BA, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis(FLINT) : a multicentre, randomised, placebo-controlled trial", Lancet, 385, pp.956~965 (2015)
53. Friedman SL, "A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis", Hepatology, 67, pp.1754~1767 (2018)
54. Kim D, "Nonobese fatty liver disease", Clin Gastroenterol Hepatol, 15, pp.474~485 (2017)
55. Leung JC, "Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients", Hepatology, 65, pp.54~64 (2017)
56. Wood NJ, "Liver : nonobese individuals in the developing world are at risk of nonalcoholic fatty liver and liver disease", Nat Rev Gastroenterol Hepatol, 7, pp.357~ (2010)
57. Das K, "Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease", Hepatology, 51, pp.1593~1602 (2010)
58. Hyun Chin Cho, "Prevalence and Factors Associated with Nonalcoholic Fatty Liver Disease in a Nonobese Korean Population", Gut and Liver, 10(1), pp.117~125 (2016), 거트앤리버 소화기연관학회협의회
59. Das K, "Lean NASH : distinctiveness and clinical implication", Hepatol Int, 7(Suppl 2), pp.806~813 (2013)
60. Kwon YM, "Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults", Am J Gastroenterol, 107, pp.1852~1858 (2012)
61. Chang Y, "Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men", Gut, 58, pp.1419~1425 (2009)
62. Stevens J, "Selection of measures in epidemiologic studies of the consequences of obesity", Int J Obes (Lond), 32(Suppl 3), pp.S60~S66 (2008)
63. WHO Expert Consultation, "Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies", Lancet, 363, pp.157~163 (2004)
64. Kohli S, "Differences in subcutaneous abdominal adiposity regions in four ethnic groups", Obesity(Silver Spring), 21, pp.2288~2295 (2013)
65. Phan-Hug F, "Genetic testing in patients with obesity", Best Pract Res Clin Endocrinol Metab, 26, pp.133~143 (2012)
66. Hernaez R, "Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey", Clin Gastroenterol Hepatol, 11, pp.1183~1190 (2013)
67. Sookoian S, "Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene(PNPLA3)on the susceptibility and histological severity of nonalcoholic fatty liver disease", Hepatology, 53, pp.1883~1894 (2011)
68. Romeo S, "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
69. Liu YL, "Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma", J Hepatol, 61, pp.75~81 (2014)
70. Rotman Y, "The association of genetic variability in patatin-like phospholipase domain-containing protein 3(PNPLA3)with histological severity of nonalcoholic fatty liver disease", Hepatology, 52, pp.894~903 (2010)
71. Speliotes EK, "PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease", Hepatology, 52, pp.904~912 (2010)
72. Wei JL, "Prevalence and severity of nonalcoholic fatty liver disease in nonobese patients : a population study using proton-magnetic resonance spectroscopy", Am J Gastroenterol, 110, pp.1306~1314 (2015)
73. Ioannou GN, "Beyond obesity: is cholesterol-induced liver injury the cause of non-alcoholic steatohepatitis?", J Gastroenterol Hepatol, 27, pp.1412~1414 (2012)
74. Adams LA, "Cholesteryl ester transfer protein gene polymorphisms increase the risk of fatty liver in females independent of adiposity", J Gastroenterol Hepatol, 27, pp.1520~1527 (2012)
75. Musso G, "Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis", Prog Lipid Res, 52, pp.175~191 (2013)
76. Caballero F, "Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH", J Hepatol, 50, pp.789~796 (2009)
77. Musso G, "Sterol regulatory element-binding factor 2(SREBF-2)predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism", Diabetes, 62, pp.1109~1120 (2013)
78. Wieckowska A, "Diagnosis of nonalcoholic fatty liver disease : invasive versus noninvasive", Semin Liver Dis, 28, pp.386~395 (2008)
79. Torres DM, "Diagnosis and therapy of nonalcoholic steatohepatitis", Gastroenterology, 134, pp.1682~1698 (2008)
80. Machado MV, "Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal", J Hepatol, 58, pp.1007~1019 (2013)
81. Yasutake K, "Nutritional investigation of non-obese patients with nonalcoholic fatty liver disease : the significance of dietary cholesterol", Scand J Gastroenterol, 44, pp.471~477 (2009)
82. Kwak JH, "Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: a cross-sectional study", Clin Nutr (2017)[DOI]

관련 논문AI추천